Ultragenyx Pharmaceutical Inc
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
Capital expenditures decreased by 14% from FY24 to FY25.
Current Price
$24.77
+0.32%GoodMoat Value
$28.14
13.6% undervaluedUltragenyx Pharmaceutical Inc (RARE) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of Ultragenyx Pharmaceutical Inc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $673.00M. Gross profit (TTM) is $564.00M. EBITDA is $-536.00M. Earnings per share (EPS) is $-5.83. The P/E ratio is -4.16. Market capitalization is $2.39B.
Free cash flow (FCF) is $-472.00M. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use Ultragenyx Pharmaceutical Inc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.
